- tech360.tv
Neuralink's 'Blindsight' Implant Earns FDA Breakthrough Device Status
Neuralink's 'Blindsight' implant has received FDA breakthrough device designation. The device aims to restore vision even in those who lack eyes or optic nerves. Neuralink is also testing an implant that will allow paralysed patients to control digital devices.
Elon Musk's brain-chip startup Neuralink has made a significant breakthrough in its quest to restore vision to the blind. The company announced on Tuesday that its experimental implant, known as 'Blindsight,' has received the coveted 'breakthrough device' designation from the US Food and Drug Administration (FDA).
This prestigious designation is reserved for medical devices that demonstrate promise in treating life-threatening conditions, and it is intended to expedite the development and review process. The announcement represents a significant step forward for Neuralink's ambitious vision restoration project.
Musk, known for his bold claims, stated on social media platform X that the Blindsight device "will enable even those who have lost both eyes and their optic nerve to see". While this assertion has yet to be proven, it highlights the potential impact of the technology if successful.
Neuralink, founded in 2016 by Musk and a team of engineers, is developing brain-computer interface technology that has the potential to revolutionise the treatment of neurological conditions. The company's primary focus has been on creating a brain chip implant that can be surgically implanted into the skull.
The ultimate goal of this technology goes beyond vision restoration. Neuralink aims to help disabled patients regain their ability to move and communicate independently. The implant consists of a chip that processes and transmits neural signals, potentially allowing users to control digital devices with their thoughts alone.
In addition to the Blindsight project, Neuralink is currently testing an implant designed to assist paralysed patients. This separate study, which aims to enrol three patients, is expected to last several years and will assess the device's ability to control digital devices using neural signals.
The company has already made significant progress in this regard. Earlier this year, Neuralink successfully implanted its device in a second patient, who has since used it to play video games and learn 3D object design. This demonstrates that the technology has real-world applications beyond medical treatments.
Neuralink's 'Blindsight' implant receives FDA breakthrough device designation
The device aims to restore vision, even for those without eyes or optic nerves
Neuralink is also testing an implant to help paralysed patients control digital devices
Source: REUTERS